Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 666.7 g/mol |
---|---|
Molecular Formula | C28H38N6O11S |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 14 |
Rotatable Bond Count | 12 |
Exact Mass | 666.23192722 g/mol |
Monoisotopic Mass | 666.23192722 g/mol |
Topological Polar Surface Area | 250 A^2 |
Heavy Atom Count | 46 |
Formal Charge | 0 |
Complexity | 1070 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 8 | |
---|---|
Drug Name | Revatio |
PubMed Health | Sildenafil |
Drug Classes | Antihypertensive, Peripheral Vasodilator, Erectile Dysfunction Agent, Vasodilator |
Drug Label | REVATIO, phosphodiesterase-5 (PDE-5) inhibitor, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE-5). Sildenafil is also marketed as VIAGRA for erectile dysfunct... |
Active Ingredient | Sildenafil citrate |
Dosage Form | Tablet; Solution; For suspension |
Route | Oral; Intravenous |
Strength | eq 20mg base; eq 10mg base/ml; eq 10mg base/12.5ml (eq 0.8mg base/ml) |
Market Status | Prescription |
Company | Pfizer |
2 of 8 | |
---|---|
Drug Name | Sildenafil citrate |
Drug Label | VIAGRA, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).Sildenafil citrate is designated chemically as 1-[[3-(6,7-d... |
Active Ingredient | Sildenafil citrate |
Dosage Form | Tablet |
Route | oral |
Strength | 25mg; 100mg; 50mg |
Market Status | Tentative Approval |
Company | Macleods Pharma |
3 of 8 | |
---|---|
Drug Name | Sildenafil citrate |
PubMed Health | Sildenafil |
Drug Classes | Antihypertensive, Peripheral Vasodilator, Erectile Dysfunction Agent, Vasodilator |
Drug Label | VIAGRA, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).Sildenafil citrate is designated chemically as 1-[[3-(6,7-d... |
Active Ingredient | Sildenafil citrate |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | eq 100mg base; 25mg; eq 50mg base; eq 20mg base; 100mg; 50mg; eq 25mg base |
Market Status | Tentative Approval; Prescription |
Company | Amneal Pharms; Mylan Pharms; Hetero Labs Ltd V; Mylan Pharma; Actavis Pharma; Apotex; Torrent Pharms; Watson Labs; Actavis Grp Ptc; Teva Pharms; Macleods Pharms; Dr Reddys Labs |
4 of 8 | |
---|---|
Drug Name | Viagra |
Drug Label | VIAGRA, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).Sildenafil citrate is designated chemically as 1-[[3-(6,7-d... |
Active Ingredient | Sildenafil citrate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 100mg base; eq 50mg base; eq 25mg base |
Market Status | Prescription |
Company | Pfizer Ireland |
5 of 8 | |
---|---|
Drug Name | Revatio |
PubMed Health | Sildenafil |
Drug Classes | Antihypertensive, Peripheral Vasodilator, Erectile Dysfunction Agent, Vasodilator |
Drug Label | REVATIO, phosphodiesterase-5 (PDE-5) inhibitor, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE-5). Sildenafil is also marketed as VIAGRA for erectile dysfunct... |
Active Ingredient | Sildenafil citrate |
Dosage Form | Tablet; Solution; For suspension |
Route | Oral; Intravenous |
Strength | eq 20mg base; eq 10mg base/ml; eq 10mg base/12.5ml (eq 0.8mg base/ml) |
Market Status | Prescription |
Company | Pfizer |
6 of 8 | |
---|---|
Drug Name | Sildenafil citrate |
Drug Label | VIAGRA, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).Sildenafil citrate is designated chemically as 1-[[3-(6,7-d... |
Active Ingredient | Sildenafil citrate |
Dosage Form | Tablet |
Route | oral |
Strength | 25mg; 100mg; 50mg |
Market Status | Tentative Approval |
Company | Macleods Pharma |
7 of 8 | |
---|---|
Drug Name | Sildenafil citrate |
PubMed Health | Sildenafil |
Drug Classes | Antihypertensive, Peripheral Vasodilator, Erectile Dysfunction Agent, Vasodilator |
Drug Label | VIAGRA, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).Sildenafil citrate is designated chemically as 1-[[3-(6,7-d... |
Active Ingredient | Sildenafil citrate |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | eq 100mg base; 25mg; eq 50mg base; eq 20mg base; 100mg; 50mg; eq 25mg base |
Market Status | Tentative Approval; Prescription |
Company | Amneal Pharms; Mylan Pharms; Hetero Labs Ltd V; Mylan Pharma; Actavis Pharma; Apotex; Torrent Pharms; Watson Labs; Actavis Grp Ptc; Teva Pharms; Macleods Pharms; Dr Reddys Labs |
8 of 8 | |
---|---|
Drug Name | Viagra |
Drug Label | VIAGRA, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).Sildenafil citrate is designated chemically as 1-[[3-(6,7-d... |
Active Ingredient | Sildenafil citrate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 100mg base; eq 50mg base; eq 25mg base |
Market Status | Prescription |
Company | Pfizer Ireland |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
76
PharmaCompass offers a list of Sildenafil Citrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sildenafil Citrate manufacturer or Sildenafil Citrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sildenafil Citrate manufacturer or Sildenafil Citrate supplier.
PharmaCompass also assists you with knowing the Sildenafil Citrate API Price utilized in the formulation of products. Sildenafil Citrate API Price is not always fixed or binding as the Sildenafil Citrate Price is obtained through a variety of data sources. The Sildenafil Citrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A UK-9248010 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of UK-9248010, including repackagers and relabelers. The FDA regulates UK-9248010 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. UK-9248010 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of UK-9248010 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A UK-9248010 supplier is an individual or a company that provides UK-9248010 active pharmaceutical ingredient (API) or UK-9248010 finished formulations upon request. The UK-9248010 suppliers may include UK-9248010 API manufacturers, exporters, distributors and traders.
click here to find a list of UK-9248010 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A UK-9248010 DMF (Drug Master File) is a document detailing the whole manufacturing process of UK-9248010 active pharmaceutical ingredient (API) in detail. Different forms of UK-9248010 DMFs exist exist since differing nations have different regulations, such as UK-9248010 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A UK-9248010 DMF submitted to regulatory agencies in the US is known as a USDMF. UK-9248010 USDMF includes data on UK-9248010's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The UK-9248010 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of UK-9248010 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The UK-9248010 Drug Master File in Japan (UK-9248010 JDMF) empowers UK-9248010 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the UK-9248010 JDMF during the approval evaluation for pharmaceutical products. At the time of UK-9248010 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of UK-9248010 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a UK-9248010 Drug Master File in Korea (UK-9248010 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of UK-9248010. The MFDS reviews the UK-9248010 KDMF as part of the drug registration process and uses the information provided in the UK-9248010 KDMF to evaluate the safety and efficacy of the drug.
After submitting a UK-9248010 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their UK-9248010 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of UK-9248010 suppliers with KDMF on PharmaCompass.
A UK-9248010 CEP of the European Pharmacopoeia monograph is often referred to as a UK-9248010 Certificate of Suitability (COS). The purpose of a UK-9248010 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of UK-9248010 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of UK-9248010 to their clients by showing that a UK-9248010 CEP has been issued for it. The manufacturer submits a UK-9248010 CEP (COS) as part of the market authorization procedure, and it takes on the role of a UK-9248010 CEP holder for the record. Additionally, the data presented in the UK-9248010 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the UK-9248010 DMF.
A UK-9248010 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. UK-9248010 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of UK-9248010 suppliers with CEP (COS) on PharmaCompass.
A UK-9248010 written confirmation (UK-9248010 WC) is an official document issued by a regulatory agency to a UK-9248010 manufacturer, verifying that the manufacturing facility of a UK-9248010 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting UK-9248010 APIs or UK-9248010 finished pharmaceutical products to another nation, regulatory agencies frequently require a UK-9248010 WC (written confirmation) as part of the regulatory process.
click here to find a list of UK-9248010 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing UK-9248010 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for UK-9248010 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture UK-9248010 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain UK-9248010 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a UK-9248010 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of UK-9248010 suppliers with NDC on PharmaCompass.
UK-9248010 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of UK-9248010 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right UK-9248010 GMP manufacturer or UK-9248010 GMP API supplier for your needs.
A UK-9248010 CoA (Certificate of Analysis) is a formal document that attests to UK-9248010's compliance with UK-9248010 specifications and serves as a tool for batch-level quality control.
UK-9248010 CoA mostly includes findings from lab analyses of a specific batch. For each UK-9248010 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
UK-9248010 may be tested according to a variety of international standards, such as European Pharmacopoeia (UK-9248010 EP), UK-9248010 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (UK-9248010 USP).